List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
U.S. V. Bayer AG and Monsanto Company Comment: the Sierra Club
ATTN: Kathleen S. O'Neill Chief, Transportation, Energy & Agriculture Section Antitrust Division United States Department of Justice 450 5th Street, NW, Suite 800 Washington, DC 20530 Petition in opposition to proposed U.S. v. Bayer AG and Monsanto Company settlement and merger: A merger of agrochemical giants Bayer and Monsanto would create the world's largest seed and pesticide maker. I am afraid this move will reduce competition, raise prices for consumers and farmers, and result in an unacceptable degree of control over the agricultural industry and our food supply. I am very concerned about pollinators and the increased risks to bees, butterflies and birds with the increase of Bayer's neonicotinoids. Both companies produce corn products engineered to imply the use of harmful pesticides they manufacture. The production of corn uses high amounts of nitrogen- based fertilizers and the excess sediment is contaminating our waterways, therefore I am deeply worried about increased corn production from this merger. The heavy nutrient runoff from corn is widely attributed to exacerbating the marine "Dead Zone" in the Gulf of Mexico, in which algal blooms create hypoxic conditions wherein oxygen concentration is in such low levels that marine life suffocates and dies. I urge the Department of Justice to do more prevent the Bayer-Monsanto seed and pesticide platform from growing too strong by stopping this merger. If this merger is allowed, it should require more pesticide and seed divestments in order to protect our agriculture and food supply. This merger is anti-competition, if it is approved it will fail to protect farmers, consumers and the environment by allowing further consolidation of the industrial agriculture sector. -
Rules Governing the Share Capital of German Public Companies by Frank Wooldridge
Rules governing the share capital of German public companies by Frank Wooldridge he above rules are somewhat detailed and some - company. However, it contains detailed rules governing times rather complex. A good elementary account the maintenance of capital. Certain of these rules, Tof them by Schneider and Heidenhain is given in including the prohibition imposed on a public company The German Stock Corporation Act ( 2nd ed, pub Kluwer, subscribing for its own shares contained in paragraph 2000) which has been of considerable interest and help to 56 (1) AktG are considered below. The imposition of the author of this article. ancillary obligations upon shareholders is also considered below, where the rules governing the increase and The articles of a public company ( Aktiengesellschaft ) are reduction of capital, which are rather complex, are dealt required to specify the amount of the company’s share with in outline. capital, which has to be denominated in euros. The minimum capital of a public company is at present THE PROVISIONS OF PARAGRAPH 56 AKTG €50,000 (para 7 AktG ). As in the United Kingdom, shares may be issued without a par value ( Stückaktien ) or with one The most important of the abov e provisions would (Nennbetragsaktien ) (para 8(2) AktG ). Par value shares are seem to be those contained in paragraph 56(1) and 562) required to have the value of one euro or a multiple thereof AktG . Paragraph 56(1) AktG provides that a company may (para 8(2) AktG ). The shares in an Aktiengesellschaft are not subscribe for its own shares. Any purported indivisible, as are the rights attaching to each share. -
The Era of Corporate Consolidation and the End of Competition Bayer-Monsanto, Dow-Dupont, and Chemchina-Syngenta
Research Brief October 2018 The Era of Corporate Consolidation and the End of Competition Bayer-Monsanto, Dow-DuPont, and ChemChina-Syngenta DISRUPT ECOSYSTEM ACCLERATE MONOPOLY THE EFFECTS OF CORPORATE CONSOLIDATION UNDERMINE FOOD SECURITY HARM SMALL PRODUCERS HAASINSTITUTE.BERKELEY.EDU This publication is published by the Haas Institute for a Fair and Inclusive Society at UC Berkeley This research brief is part of the Haas Institute's Shahidi Project from the Global Justice Program. The Shahidi Project (Shahidi is a Swahili word meaning “witness”) intends to demystify the power structures and capacities of transnational food and agricultural corporations within our food system. To that end, researchers have developed a robust database focusing on ten of the largest food and agricultural corporations in the world. See more at haasinstitute.berkeley.edu/shahidi. About the Authors Copyeditor Support Elsadig Elsheikh is the director Marc Abizeid Special thanks to the Food of the Global Justice program and Farm Communications at the Haas Institute for a Infographics Fund, which provided the seed Fair and Inclusive Society at Samir Gambhir funding for the Shahidi project. the University of California- Berkeley, where he oversees Report Citation Contact the program’s projects and Elsadig Elsheikh and Hossein 460 Stephens Hall research on corporate power, Ayazi. “The Era of Corporate Berkeley, CA 94720-2330 food system, forced migration, Consolidation and The End of Tel 510-642-3326 human rights, Islamophobia, Competition: Bayer-Monsanto, haasinstitute.berkeley.edu structural marginality and Dow-DuPont, and ChemChina- inclusion, and trade and Syngenta.” Haas Institute for development. a Fair and Inclusive Society at the University of California, Hossein Ayazi, PhD, is a Berkeley, CA. -
Whither Plant Genetic Engineering? Allow Crops to Tolerate Environmental Stress Such As Drought, Cold, Salt, Heat, Or flood
PLANT TREK TO BOLDLY GO WHERE NO PLANT HAS GONE BEFORE On the Past, Present & Future of Plant Genetic Engineering by Richard G. Stout A HowPlantsWork.com eBook Copyright © 2013 by Richard G. Stout Version 1.0.1 PDF August, 2013 Table of Contents Preface Chapter 1: Where Do New Plants Come From? Chapter 2: How To Make A Transgenic Plant Chapter 3: Gene Guns, Terminators & Traitors Chapter 4: Farmaceuticals, Plantibodies & Edible Vaccines Chapter 5: Into The Wild Chapter 6: Are GM Plants Self-Replicating Inventions? Chapter 7: Plant Trek - The Next Generation Chapter 8: DIY Plant Genetic Engineering? Attributions About The Author Glossary about where plant biotechnology may be headed in the future, Preface including how plant biotechnology “hobbyists” may be getting into the act. Who is this book for? Please Note: This book is NOT a comprehensive textbook on plant genetic engineering and biotechnology. (If you’re looking This book is intended for people who may be curious about for such books, I’m sure you can find them at your local college plant genetic engineering, but who don’t want to read a long, bookstore or at an online bookseller.) Nor is this book meant to technical textbook on the subject. (There are provided, be a defense of genetically-engineered organisms (GMOs), however, ample links to books and articles - and also to online though I’m sure some readers will think so. Maybe here’s why. resources - for further reading.) If you’re looking for small “tastes” of information regarding various aspects of plant Since I was a graduate student in the 1970s at the University of genetic engineering, then this little book maybe just the Washington where some of the original work on transgenic informational “snack” that you’re looking for. -
Steven Sanders, Et Al. V. Bayer (AG) Aktiengesellschaft, Et Al. 03-CV-1546-Second Consolidated Amended Complaint
Q,^.IGiNAL &&,iN 2i 4- L UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -_DOF x Consolidated Civil Action IN RE BAYER AG SECURITIES No. 03 CV 1546 (WHP) LITIGATION Class Action x 71 :n = SECOND CONSOLIDATED AMENDED COMPLAINT Jury Trial Demand MILBERG WEISS BERSHAD & SCHULMAN LLP Melvyn I. Weiss (MW-1392) Michael C . Spencer (MS-8874) Lee A. Weiss (LW-1130) Jennifer Sclar (JS-7313) One Pennsylvania Plaza New York, NY 10119 (212) 594-5300 Attorneys for Lead Plaintiff January 14, 2005 i • ' Table of Contents Page SUMMARY OF CLAIMS ...............................................................................................................2 JURISDICTION AND VENUE ...................................................................................................... 8 A. General Jurisdiction and Venue ............................................................................... 8 B. Subject Matter Jurisdiction Over Claims of Foreign Purchasers on Foreign Exchanges ................................................................................................................ 8 PARTIES .......................................................................................................................................12 RELEVANT EVENTS ..................................................................................................................14 A. Background of the Statin Market ...........................................................................14 B. FDA Approval and Introduction of Baycol; Early Safety Warnings -
Agribusiness and Antitrust: the Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union
The Global Business Law Review Volume 7 Issue 1 Article 9 7-1-2018 Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union Aleah Douglas Cleveland-Marshall College of Law Follow this and additional works at: https://engagedscholarship.csuohio.edu/gblr Part of the Antitrust and Trade Regulation Commons, and the Business Organizations Law Commons How does access to this work benefit ou?y Let us know! Recommended Citation Aleah Douglas, Agribusiness and Antitrust: The Bayer-Monsanto Merger, Its Legality, and Its Effect on the United States and European Union, 7 Global Bus. L. Rev. 156 (2018) available at https://engagedscholarship.csuohio.edu/gblr/vol7/iss1/9 This Note is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been accepted for inclusion in The Global Business Law Review by an authorized editor of EngagedScholarship@CSU. For more information, please contact [email protected]. AGRIBUSINESS AND ANTITRUST: THE BAYER-MONSANTO MERGER, ITS LEGALITY, AND ITS EFFECT ON THE UNITED STATES AND EUROPEAN UNION ALEAH DOUGLAS I. INTRODUCTION……………………………………………………………………... 157 II. BACKGROUND…………………………………………………………………….....158 A. A Review of the Bayer-Monsanto Merger………………………….…………... 158 B. United States Antitrust Laws…………………………………………………… 161 1. The Applicable Laws……………………………………………………. 161 2. Problems and Antitrust Violations……………………………………… 166 3. American Agribusiness…………………………………………………. 167 C. European Union Antitrust Laws……………………………………………….. 172 1. The European Union……………………………………………………. 172 2. The Applicable Laws………………………………….………………… 172 3. Problems and Antitrust Violations……………………….………....…... 174 4. European Union Agribusiness…………….…………………………….. 176 D. Illegality and Detriment …………………………………….…………………. 178 III. CONCLUSION……………………………………………………………………....... 180 ABSTRACT This note examines the current and historical antitrust laws of the United States and the European Union as they relate to the currently pending merger between Bayer and Monsanto. -
Fordham Journal of Corporate & Financial
Fordham Journal of Corporate & Financial Law Volume 14 Issue 1 Article 3 2008 Approaching Comparative Company Law David C. Donald Follow this and additional works at: https://ir.lawnet.fordham.edu/jcfl Part of the Banking and Finance Law Commons, and the Business Organizations Law Commons Recommended Citation David C. Donald, Approaching Comparative Company Law , 14 Fordham J. Corp. & Fin. L. 83 (2008). Available at: https://ir.lawnet.fordham.edu/jcfl/vol14/iss1/3 This Article is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for inclusion in Fordham Journal of Corporate & Financial Law by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more information, please contact [email protected]. APPROACHING COMPARATIVE COMPANY LAW David C. Donald∗ ABSTRACT This Article identifies several common errors that occur in comparative law analyses, offers guidelines to help avoid such errors, and provides a framework for studying the company laws of three major jurisdictions. Part I discusses some of the problems that can arise in comparative law and offers a few points of caution that can be useful for practical, theoretical and legislative comparative law. Part II examines well-known examples of comparative analysis gone astray in order to demonstrate the utility of heeding the outlined points of caution. Part III provides an example of using functional definitions to demarcate the topic “company law,” offering an “effects” test to determine whether a given provision of law should be considered as functionally part of the rules that govern the core characteristics of companies. -
Comparative Company Law
Comparative company law 26th of September 2017 – 3rd of October 2017 Prof. Jochen BAUERREIS Attorney in France and Germany Certified specialist in international and EU law Certified specialist in arbitration law ABCI ALISTER Strasbourg (France) • Kehl (Germany) Plan • General view of comparative company law (A.) • Practical aspects of setting up a subsidiary in France and Germany (B.) © Prof. Jochen BAUERREIS - Avocat & Rechtsanwalt 2 A. General view of comparative company law • Classification of companies (I.) • Setting up a company with share capital (II.) • Management bodies (III.) • Transfer of shares (IV.) • Taxation (V.) • General tendencies in company law (VI.) © Prof. Jochen BAUERREIS - Avocat & Rechtsanwalt 3 I. Classification of companies • General classification – Partnerships • Typically unlimited liability of the partners • Importance of the partners – The companies with share capital • Shares can be traded more or less freely • Typically restriction of the associate’s liability – Hybrid forms © Prof. Jochen BAUERREIS - Avocat & Rechtsanwalt 4 I. Classification of companies • Partnerships – « Civil partnership » • France: Société civile • Netherlands: Maatschap • Germany: Gesellschaft bürgerlichen Rechts • Austria: Gesellschaft nach bürgerlichem Recht (GesnbR) • Italy: Società simplice © Prof. Jochen BAUERREIS - Avocat & Rechtsanwalt 5 I. Classification of companies • Partnerships – « General partnership » • France: Société en nom collectif • UK: General partnership (but without legal personality!) • USA: General partnership -
The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow. -
Siemens Annual Report 2019
Annual Report 2019 siemens.com Table of contents A B C Combined Consolidated Additional Information Management Report Financial Statements A.1 p 2 B.1 p 76 C.1 p 150 Organization of the Siemens Group Consolidated Statements Responsibility Statement and basis of presentation of Income C.2 p 151 A.2 p 3 B.2 p 77 Independent Auditor ʼs Report Financial performance system Consolidated Statements of Comprehensive Income C.3 p 157 A.3 p 5 Report of the Supervisory Board Segment information B.3 p 78 Consolidated Statements C.4 p 162 A.4 p 16 of Financial Position Corporate Governance Results of operations B.4 p 79 C.5 p 174 A.5 p 19 Consolidated Statements Notes and forward- looking Net assets position of Cash Flows statements B.5 p 80 A.6 p 20 Financial position Consolidated Statements of Changes in Equity A.7 p 24 B.6 p 82 Overall assessment of the economic position Notes to Consolidated Financial Statements A.8 p 26 Report on expected developments and associated material opportunities and risks A.9 p 38 Siemens AG A.10 p 40 Compensation Report A.11 p 71 Takeover-relevant information Combined Management Report Pages 1 – 74 A.1 Organization of the Siemens Group and basis of pr esentation Siemens is a technology company that is active in nearly all coun- Non-financial matters of the Group tries of the world, focusing on the areas of automation and digi- and Siemens AG talization in the process and manufacturing industries, intelligent Siemens has policies for environmental, employee and social infrastructure for buildings and distributed energy systems, con- matters, for the respect of human rights, and anti-corruption and ventional and renewable power generation and power distribu- bribery matters, among others. -
Chapter 2: Benefits and Risks of Gene Technology in Agriculture
2 %HQHILWVDQGULVNVRIJHQHWHFKQRORJ\LQ DJULFXOWXUH Introduction 2.1 Using biotechnology can be seen as extending earlier methods of plant and animal breeding which date back many thousands of years (Table 2.1).1 The technology obtains results more rapidly, is more precise, and gives access to a broader genetic base than traditional breeding techniques. These are the features that recommend its use so powerfully to plant and animal breeders. It provides an important tool when integrated with traditional breeding approaches. 2.2 The precision that gene technology offers is possible because the exact segment of a chromosome that determines a desired trait can be identified. With this capacity, traditional breeding programs can be fast tracked by locating seeds or offspring at an early stage, through gene marker technology, and breeding only from them. The Cattle Council of Australia commented on the dramatic increases in precision of genetic improvement that is possible as a result.2 In addition, genes can be removed from one organism and inserted into another. 2.3 Transgenesis, in which genes are moved from one species or organism to another, allows beneficial genes from any source to be transferred to other species or organisms. The Cooperative Research Centre (CRC) for Tropical Plant Pathology pointed out that, while conventional breeding programs have improved the pest and disease resistance of Australian crops, there 1 C Hudson, 'How industry adopts new technology', Gene Technology and Food, National Science & Industry Forum Report, Australian Academy of Science, April 1999, p. 12; Nugrain, Submission no. 25, p. 6. 2 Cattle Council of Australia, Submission no. -
Notes to the Consolidated Financial Statements of the Bayer Group
Five-Year Summary Bayer Annual Report 2018 Five-Year Summary 2014 2015 2016 2017 2018 Bayer Group (€ million) Sales 41,339 46,085 34,943 35,015 39,586 EBITDA1 8,315 9,573 8,801 8,563 10,266 1 EBITDA before special items 8,685 10,256 9,318 9,288 9,547 1 EBITDA margin before special items (in %) 21.0 22.3 26.7 26.5 24.1 EBIT1 5,395 6,241 5,738 5,903 3,914 1 EBIT before special items 5,833 7,060 6,826 7,130 6,480 Income before income taxes 4,414 5,236 4,773 4,577 2,318 Net income (from continuing and discontinued operations) 3,426 4,110 4,531 7,336 1,695 1 Earnings per share (from continuing and discontinued operations) (€) 4.14 4.97 5.44 8.29 1.80 1 Core earnings per share (from continuing operations) (€) 5.89 6.82 6.67 6.64 5.94 Net cash provided by operating activities (from continuing and discontinued operations) 5,810 6,890 9,089 8,134 7,917 Net financial debt 19,612 17,449 11,778 3,595 35,679 2 Capital expenditures (as per segment table) 2,484 2,554 2,627 2,418 2,564 Bayer AG Total dividend payment 1,861 2,067 2,233 2,402 2,611 Dividend per share (€) 2.25 2.50 2.70 2.80 2.80 Innovation Research and development expenses (€ million) 3,537 4,274 4,405 4,504 5,246 Ratio of R&D expenses to sales – Pharmaceuticals (%) 15.6 16.0 16.7 16.2 15.5 Ratio of R&D expenses to sales – Crop Science (%) 10.3 10.7 11.7 11.7 13.0 Employees in research and development3 13,900 14,753 14,213 14,041 17,275 Employees 3 Number of employees (Dec.